Study on Venetoclax, Lenalidomide, and Rituximab for Untreated Mantle Cell Lymphoma

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of Mantle Cell Lymphoma (MCL).
• Show signs or symptoms of MCL based on lab tests, scans, or physical exams.
• Be in relatively good health with an ECOG performance status of 0 to 2, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Must be enrolled in the Revlimid REMS® program and agree to follow its requirements.
• Women who can become pregnant must agree to regular pregnancy testing as part of the Revlimid REMS® program.
• Men and women of childbearing potential must use effective birth control.
• Have good organ function based on medical tests.
• Be able to understand the study and agree to sign informed consent.
• Be able to swallow pills.

Exclusion Criteria

• Have received chemotherapy for MCL before.
• Are pregnant or breastfeeding.
• Have moderate to severe nerve damage.
• Have a history of MCL affecting the brain or spinal cord.
• Have serious heart disease.
• Have any condition that affects how the body absorbs medication.
• Have an uncontrolled infection or have needed IV antibiotics within two weeks before starting the study.
• Have had a stroke or brain bleed within six months before starting the study.
• Are participating in another clinical trial.
• Have taken certain medications that affect drug metabolism within a week before starting the study.
• Have mental health or social issues that would prevent following the study requirements.
• Are HIV positive.
• Have active Hepatitis B or C infection.
• Have had another cancer, unless it was treated and has not returned for at least two years, or it is a type that does not affect life expectancy.